¥D­¶ > ¤¤ÃĬã¨s > ¶Ç²Î¤¤¯óÃĤ§¦w¥þ©Ê¤Î¬r©Êµû¦ô
 
¶Ç²Î¤¤¯óÃĤ§¦w¥þ©Ê¤Î¬r©Êµû¦ô

>>¶Ç²Î¤¤Âå¾Ç¹ïÃĪ«¬r©Êªº²z¸Ñ
>>²{¥N¦èÃÄ»P¯ó¥»ÃĪ«¤§§O
>>¯ó¥»ÃĪ«ªº¦w¥þµû¦ô
>>¯óÃĦw¥þ©Êµû¦ôªº¬D¾Ô
>>°Ñ¦Ò½×¤å


¦b¹L¥h¤Q¦~¶¡¡A¤¤ÃĪvÀø³vº¥´¶¤Î¡A¤H­Ì¼sªx§Q¥Î¦¹ÃþÀøªk¨Ó¨¾ªv¯e¯f¡C«Ü¦h¤H»~»{¬°¯óÃĨӦۤѵM¡A¨äÃÄ©Ê·Å©M¡A¥²©w¦w¥þµL¬r¡C¨Ï¥Î¤£·í©¹©¹²£¥Í¤£¨}¤ÏÀ³¡A©Î¦³¾÷·|»P¨ä¥LªvÀøÃĪ«²£¥Í¬Û¤¬§@¥Î¡C¥Ø«e¹ï¯ó¥»ÃĪ«ªº¨Ï¥Î¤´µM¯Ê¥F²`¤J»{ÃÑ¡A¶Ç²Î¤¤¯óÃĪº¬r©Ê¤Î¦w¥þ©Ê°ÝÃD¡A²{¤w¦¨¬°¯]¦¿¤T¨¤¬w¬Æ¦Ü»·¦Ü¥@¬É¤§¤¤ÂåÃĵo®iªº¨ä¤¤¤@­Ó¼öªù°Q½×¡C


¶Ç²Î¤¤Âå¾Ç¹ïÃĪ«¬r©Êªº²z¸Ñ


¨Æ¹ê¤W¡A¤ÑµMªºª«½è¤£¤@©w¬O¦w¥þµL¬rªº¡C¦b¨Ï¥Î¯óÃÄ«e¥²¥ý²M·¡ÁA¸Ñ¦w¥þ¨Ï¥Î­nÂI¡C¥j¥N¤¤Âå»{¬°¡A¤HÅé±w¯f¬O¥Ñ©ó¾÷Åé³±¶§°¾³Ó°¾°I¡A¦Ó§Q¥ÎÃĪ«ªº°¾©Ê¥i¥HªÈ¥¿³oºØ¥¢¿Åª¬ºA¡A¨Ï¤§Âk©ó¥­©M¡C¨ä¤¤ÃÄ©Ê·U¬O®m¯P·U¤£¯à¹L¥Î¡A¥H§K·l¶Ë¥¿®ð¡C®Ú¾Ú¯óÃĪº¦w¥þ©Ê¤Î¬r©Ê¡A¶Ç²Î¤W¤À¬°¤j¬r¡B¤p¬r¡BµL¬r¤TÃþ¡C¦³¤j¬rªº¤¤Ãĸû©ö¥X²{¥ð§J¡Bäú¤ß¡B¤f®B¥|ªÏ³Â·ôµ¥ÄY­«°Æ§@¥Î¡A¦p¥Í¤Ú¨§¤Î¥Íªþ¤lµ¥¡F¦³¤p¬rªº¤¤ÃÄ¡A¦pªG¥Î¶q¹L¤j«h·|¥X²{»´·L©I§l§xÃø¡B¤ß²v¤£¥¿±`¡BÀY·wµ¥°Æ§@¥Î¡A¤ñ¦p¥_§ö¤Î¥ÕªG¡F¦ÓµL¬rªº¤¤ÃÄ«hÃĩʤñ¸û¥­©M¡A¸û¤Ö¥X²{°Æ§@¥Î¡C(°Ñ¦Ò¬ÛÃö¤º®e)


¬°¤F´î»´¬r©Ê©M¼W±jÃĮġA¤¤Â妳¤@®M§¹¾ãªº¥ÎÃIJz½×©M¦æ¤§¦³®Äªº¾Þ§@¤èªk¡A¨Ò¦pÃĪ«¬¶»s¥[¤u¡A¤è¾¯°t¥î(§g¦Ú¦õ¨Ï)¡A´ö¾¯·ÎªA¤èªkµ¥µ¥¡CÁ`¬A¦Ó¨¥¡A³q¹L¿ëµý¥ÎÃÄ¡A¥¿½T¥ÎÃÄ¡A¤¤ÃĪº¬r°Æ§@¥Î«Ü¤Ö¥X²{¡C

­¶³»

²{¥N¦èÃÄ»P¯ó¥»ÃĪ«¤§§O


²{¥N¦èÃÄ¥D­n³z¹L³æ¤@¼Ð¹v»¤µoÅ餺¯S©wªº¥NÁ¤ÏÀ³¨Ó²£¥ÍÃĮġAÃĪ«¦P®É²£¥Í¤£¦Pµ{«×ªº°Æ§@¥Î¡C¬Û¤Ï¡A¤¤¯óÃÄ¥H¦h¼Ð¹v¤è¦¡¹ï¨­Åé²£¥Í¦h¤è­±ªº¥Í²z¤ÏÀ³¡C³o¨Ç¥Í²z¤ÏÀ³¬Û¤¬§@¥Î¡A¨Ï¨­Åé¥X²{ªº°Æ§@¥Î¤ñ¸û·Å©M¡C


¦èÃĬã¨s¥HÄÄ©ú¯e¯f¾÷²z¬°©lÂI¡AµM«á¹ï¬ÛÃöªº¼Ð¹v¤Î¤Æ¦Xª«¶i¦æ¿ë§O¡B½T»{¤Î¼Ð·Ç¤Æ¡C§Y¬O»¡¡A¦b¬ãµoÃĪ«®É¡A¬ì¾Ç®a¥HÁA¸Ñ¤HÅé¤Î¨ä¯e¯fªº¾÷²z¬°°ò¦¡A³z¹L¹êÅç¨Ó¿z¿ï¤j¶q¤Æ¾Ç¤À¤l¡A¥H§ä¥X¹ï¬Y¤@¯e¯f³Ì¨ã®Ä¥Î¤Î¸û¤Ö¬r©Êªº¤À¤l¡C


¶Ç²Î¤¤ÃĪvÀø¨ã¦³¾ãÅé½Õ¸`§@¥Î¡A¥D­n³z¹L¹ï¨­Åé¾÷¯àª¬ºAµû¦ô¡A°t¦X¦UºØ´Óª«°t¥î¡A¨Óµo´§ºî¦XªvÀø¥Øªº¡C¤j¦h¼Æ¯óÃÄ¥»¨­§t¦³½ÆÂøªº¦¨¤À¡A¨Ò¦p萜Ãþ¡B¥Íª«ÆP¡B¦h¿}¤Î¨ä¥L¤Æ¾Çª«½èµ¥¡C³o¨Ç½ÆÂø¦¨¤À¯à½w½Ä¡B¨ó¦P©M§ïÅܯóÃĤº¦U¥D­n¦¨¤À¡A¨Ï¤§²£¥Í§ó²z·Qªº®Ä¥Î¡C¦]¦¹¡A´Óª«´£¨úª«¨Ã¤£¥i¨ú¥N¾ã´Ê´Óª«ªº®Ä¥Î¡A¦Ó³æ¤@¤Æ¦Xª«¤§¬ã¨sµ²ªG«Ü®e©ö»P¾ã´Ê´Óª«²£¥Í²V¶Ã¡A³y¦¨¿ù»~ªº¬ì¾Ç¼Æ¾Ú¡C¤¤Ãij¶ÀªºÀ³¥Î´N¬O¤@­Ó¨Ò¤l¡C



³Â¶À¬O¶Ç²Î¤¤Âå±`¥ÎÃÄ¡A¦h¥Î©ó¤ä®ðºÞ­ý³Ý¡B«y¹Â¡B·P«_¡B¯B¸~µ¥ªvÀø¡C¥Ñ©ó¦³Á{§É¼Æ¾ÚÅã¥Üªø´ÁªA¥Î³Â¶À¦³§UèªÎ¤H¤h´î­«¡C1,2 ¦]¦Ó¸g±`¥[¤J¸É¥R¾¯¤¤¡A§@´îªÎ¥Î«~¼sªx¾P°â¡C¥t¥~¡A³Â¶ÀÆP¬O³Â¶Àªº¨ä¤¤¤@ºØ¥D­n¦¨¤À¡A³Â¶Àªº½è¶q¥iµø¥G¥¦¥»¨­³Â¶ÀÆPªº§t¶q¨Óµû©w¡C¥i¬O¡A³Â¶ÀÆPªº§t¶q«o¨ú¨M©ó´Óª«ªº«~ºØ¡B´Óª«ªº³¡¦ì¡B¦a²zÀô¹Ò¡B¦¬³Î®É¶¡µ¥µ¥¡A«ÜÃø¦³²Î¤@ªº¼Ð·Ç¡C3 °£³Â¶ÀÆP¥~¡A³Â¶À©Ò§tªº¨ä¥L¦¨¤À¥ç¦³§U½w½Ä¡B¨ó¦P©M§ïÅܸÓÃĪºÃĮĩM¬r©Ê¡C¦]¦¹¡A³Â¶Àªº¬r©Êµû¦ô¨Ã¤£¯à¥H³Â¶ÀÆPªº§t¶q§@°ß¤@°Ñ¦Ò¼Ð·Ç¡C4

­¶³»

¯ó¥»ÃĪ«ªº¦w¥þµû¦ô


¤j³¡¤À¯óÃĪº¬r©Ê´ú¸Õ§¡Åã¥Ü¡A¯óÃĤ¤¬r¦¨¦]¥D­n»P¨x¤¤¬r¦³Ãö¡C¨ä¥L¥Zµn©óÂå¾ÇÂø»x¤Wªº¤¤¬r³ø§i¥]¬AµÇŦ¬r©Ê¡B¯«¸g¬r©Ê¡B¦å²G¬r©Ê¡B¤ß¦åºÞ¬r©Ê¥H¤Î¤@¨Ç¾É­P°ò¦]¬ðÅܤέPÀùµ¥¡C°ò©ó¯óÃĦw¥þªº­«­n©Ê¡A¤j¶q¹ñ·sªº¥Íª«¬ì§Þ¤w¹B¥Î©ó¤¤¯óÃĦw¥þ´ú¸Õ¤W¡C


§Q¥ÎÅé¥~²Ó­M®è¶i¦æ¬r©Êµû¦ô
§Q¥Î±`¥Îªº¹êÅç§Þ³N¡A°t¦X¤£¦P²Ó­M®è¼Ò«¬¡A§@¬°¿ëÃѯóÃĬr©Ê¤Î®Ä¥Îªº¤èªk¡C³o¨Ç§Þ³N¶·´£¨ú´Óª«¤¤¥D­n¦¨¤À¡A¥H¤£¦P¿@«×¦b²Ó­M®è¤¤°ö¾i¡C¦b¯S©wªº®É¶¡¤U¡A¯óÃĪº²Ó­M¬r©Ê¥i³z¹LÅã·LÃè²Ó­M«¬ºA¤ÀªR¡B²Ó­M¬¡©Ê´ú¸Õ¤Î¨Å»Ä²æ²B酶¬¡©Ê´ú¸Õµ¥¤èªk¶i¦æ¤ÀªR¡C5


³o¨Ç´ú¸Õ¤èªkªºÀuÂI¬O¥i¦P®É¶i¦æ¦h¶µ¹ï·Ó¤ñ¸û¡A¦¨¬°³Q¤½»{ªºÃĪ«¦w¥þ©Ê¤Î¬r©Êµû¦ô¤èªk¡C¥i¬O¡A©¹©¹¥u¯à¥Î©ó³æ¤@ªº´£¨ú¦¨¤À¡A«ÜÃø¥þ­±¦a¤ÀªR¯óÃĪºÃIJz¤Î¬r©Ê¡C


§Q¥Î°Êª«¶i¦æ¬r©Êµû¦ô
¤HÅé¬O¤@¦³¾÷¾ãÅé¡A¦U­Ó²Ó­M¤Î²Õ´¨Ã«D¿W¥ß¦s¦b¡A¦Ó¬O¤¬¬Û¨Ì¦s¡C¦]¦¹¡A¯óÃĤγæ¤@¥D­n¦¨¤À´£¨úª«¦bÅ餺¥Í²zÀô¹Òªº¹B§@¾÷²z¥²¶·³z¹L°ÊºAÅ餺¹êÅç¨Ó´ú¸Õ¡C®Ú¾Ú¤¤Âå²z½×¡A¥H¿ëµý½×ªv¨Ó¿ï¾Ü°Êª«¹êÅç¼Ò«¬¡A¥i¥HÀò±o§ó½T¤Áªºµ²ªG¡A¤£¹L·|¥Oµû¦ô¤èªkÅܱo§ó½ÆÂø¡C

­¶³»

¯óÃĦw¥þ©Êµû¦ôªº¬D¾Ô


¦³Ãö¯óÃĪº©R¦Wªk¡B«~½è±±¨î©M¯óÃĪº»{ÃÒ³£¬O¤¤¯óÃĬì¬ã©ÒÃöª`ªº°ÝÃD¡CÁöµM¬ü°ê­¹ª«¤ÎÃĪ«ºÞ¨î§½¹ï¤¤¯óÃĹêÅç¤ÎÁ{§É¬ã¨s½è¯Àªº­n¨D¡A¬Û¹ï¦a¸û¦èÃĵù¥U©Ò­n¨Dªº§C¡A¦ý´£°ª«~½è±±¨î¡A¥[±j¸gÅç¡B±Ð¨|¤Î¯óÃĸê°Tªº¥æ¬y¡A·|¥O®ø¶OªÌ¡BÂå¥Í¤Î¬ì¬ã¤H­û¹ï¤¤¯óÃħ󦳫H¤ß¡C


¹B¥Î¦è¤èÂå¾Ç¬ã¨s¤èªk©ó¯óÃĬr©Ê¬ã¨s¬O¬ì¾Ç¬É¨ãª§Ä³ªº½ÒÃD¡C¬ì¬ã¤H­û§Q¥Î¯óÃĤ¤³æ¤@´£¨úª«¨Ó¶i¦æÁ{§É«e¬r©Ê¬ã¨s¡A³o©¹©¹¤£¯à¥Nªí¥þ®è´Óª«¡A¦]¬°´Óª«ªº¬r©Ê¬O¨ü´Óª«ùئUºØª«½èªº¬Û¤¬§@¥Î©Ò¼vÅT¡C¦AªÌ¡A¤Ñ®ð¦]¯À¡B´Óª«ªº¦¨¼ôµ{«×¤Î¤gÄ[½è¯À¡A«D±`¼vÅT¯óÃĪºÃIJz¯S©Ê¡A³y¦¨·í¤¤ªº¤Æ¦X¦¨¤À¦³«Ü¤jÅܤơA¬Æ¦Ü¤£¯à¦ô­p¡C

­¶³»

°Ñ¦Ò½×¤å

1. Astrup, A., Toubro, S., et al. Pharmacology of thermogenic drugs. Am. J. Clin. Nutr. 55, 246S-248S (1992). ºK­n
2. Dulloo, A.G., Stock, M.J. Ephedrine as a thermogenic drug. Int. J. Obes. 17 (Suppl. 1), S1-S2 (1993).
3. Lee, M.K., Hsieh, D.P.H., et al. Cytotoxicity assessment of Ma-huang (Ephedra) under different conditions of preparation. Toxicological Sci. 56, 424-430 (2000). ºK­n
4. FDA (Food and Drug Administration). Dietary supplements containing ephedrine alkaloids; proposed rule. Federal Register 62, 30678-30724. (1997)
5. Saad, B., Said O., et al. Safety of traditional Arab herbal medicine. eCAM 3, 433-439 (2006). ºK­n

­¶³»

¼¶¤å
Stan Man, Integrated Chinese Medicine Holdings Ltd.

­¶³»